EXCLUSIVE The pantry biohacker: I reduced my biological age by 10 YEARS with easy diet changes anyone can do - proving you don't have to be a billionaire to turn back the clock
Longevity is having a moment.
From tech billionaires testing stem cell transfusions from their teenage sons to hyperbaric oxygen chambers and infrared saunas, it seems 'reverse ageing' is the latest obsession of the super-rich.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Amgen's gastric cancer drug meets late-stage trial goal
June 30 (Reuters) - Amgen (AMGN.O), opens new tab said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Reuters
2 hours ago
- Reuters
Google strikes deal to buy fusion power from MIT spinoff Commonwealth
WASHINGTON, June 30 (Reuters) - Alphabet's (GOOGL.O), opens new tab Google said on Monday it has struck a deal to buy power from a project in Virginia fueled by fusion, the reaction that powers the sun and the stars but is not yet commercial on Earth. Google signed what it called the technology's first direct corporate power purchase agreement with Commonwealth Fusion Systems, a company that spun off from the Massachusetts Institute of Technology in 2018. The deal is for 200 megawatts of power, about enough to power a small city, from CFS's ARC project that is being developed in Virginia, home to the world's biggest hub of energy-hungry data centers. Financial details of the deal were not disclosed. Physicists at national laboratories and companies have been trying for decades to use lasers or, in the case of CFS, large magnets to foster fusion reactions, in which light atoms are forced together to release large amounts of energy. In 2022, the Lawrence Livermore National Laboratory in California briefly achieved net energy gain in a fusion experiment using lasers. But achieving so-called "engineering break-even," in which more energy comes out of a reaction than the overall energy that goes into a fusion plant to get a reaction going, has been elusive. And for a plant to generate power from fusion, the reactions must be constant, not rare. "Yes, there are some serious physics and engineering challenges that we still have to work through to make it commercially viable and scalable," Michael Terrell, Google's head of advanced energy, told reporters in a call. "But that's something that we want to be investing in now to realize that future." As artificial intelligence and data centers boost power demand around the world, interest in fusion is spiking. Fusion, unlike nuclear fission, in which atoms are split, does not generate large amounts of radioactive waste. In addition, fusion, if successful, could help fight climate change. CFS aims to generate power from the 400 MW project known as ARC in the early 2030s but must first clear the scientific hurdles. "Without partnership and without being bold and setting a goal and going for it, you won't ever reach over those challenges," Bob Mumgaard, CFS's CEO and co-founder, told reporters. He said the ARC plant will teach CFS about the "teething phase" of fusion, in which he expects to learn about how often fusion machines break down and how they can run reliably. Google also said on Monday it was increasing its investment in CFS, but did not disclose the amount. Google was one of many investors that invested a total of $1.8 billion into CFS in 2021. Mumgaard said Google's investment on Monday was "comparable" to its 2021 one.
Reuters
3 hours ago
- Reuters
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble
June 30 (Reuters) - INmune Bio (INMB.O), opens new tab said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plunging nearly 63% in premarket trading. The drug, XPro, is designed to target and inhibit inflammatory signals associated with a type of protein called tumor necrosis factor without suppressing the immune system. The study enrolled 208 patients with mild Alzheimer's disease (AD), or mild cognitive impairment, an early sign of the disease, who were randomly chosen to receive a weekly subcutaneous injection of XPro or a placebo for 24 weeks. The drug was safe and well-tolerated, the company said, with injection site reactions the most common adverse event.
